Halozyme Therapeutics Inc.

HALO | NASDAQ

Price Alert Chart Builder DCF Calculator

$113.53

+$2.08 (+1.87%)

Sep 22, 2026, 1:03 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Income Statement Balance Sheet Cashflow Statement Ratios

Annual Quarterly TTM

Fiscal Year Period Ending	FY 2025 Dec 30, 2025	FY 2024 Dec 30, 2024	FY 2023 Dec 30, 2023	FY 2022 Dec 30, 2022	FY 2021 Dec 30, 2021	FY 2020 Dec 30, 2020
Revenue	1.4B	1.02B	829.25M	660.12M	443.31M	267.59M
Cost of Revenue	305.44M	159.42M	192.36M	139.3M	81.41M	43.37M
Gross Profit	1.09B	855.91M	636.89M	520.81M	361.9M	224.23M
Operating Income	816.29M	551.48M	337.57M	267.53M	275.9M	144.26M
Interest Income	n/a	n/a	n/a	n/a	n/a	n/a
Pretax Income	466.88M	557.13M	348.33M	248.92M	248.52M	129.3M
Net Income	316.89M	444.09M	281.59M	202.13M	402.71M	129.09M
Selling & General & Admin	193.39M	154.34M	149.18M	143.53M	50.32M	45.74M
Research & Development	81.49M	79.05M	76.36M	66.61M	35.67M	34.24M
Other Expenses	n/a	71.05M	73.77M	43.15M	n/a	n/a
Operating Expenses	274.88M	304.43M	299.32M	253.28M	86M	79.97M
Interest Expense	18.13M	18.1M	18.76M	16.95M	7.53M	20.38M
Selling & Marketing Expenses	n/a	n/a	n/a	n/a	n/a	n/a
Cost & Expenses	580.32M	463.85M	491.68M	392.59M	167.41M	123.34M
Income Tax Expense	149.99M	113.04M	66.74M	46.79M	-154.19M	217K
Shares Outstanding (Basic)	119.84M	126.83M	131.93M	136.84M	140.65M	136.21M
Shares Outstanding (Diluted)	123.9M	129.42M	134.2M	140.61M	146.8M	141.46M
EPS (Basic)	2.64	3.50	2.13	1.48	2.86	0.95
EPS (Diluted)	2.56	3.43	2.10	1.44	2.74	0.91
EBITDA	573.05M	656.54M	451.95M	315.51M	259.04M	152.96M
EBIT	485M	575.23M	367.09M	265.87M	256.04M	149.68M
Depreciation & Amortization	88.05M	81.31M	84.86M	49.64M	3M	3.28M